首页> 美国卫生研究院文献>Annals of Oncology >Editors choice: A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

【2h】

Editors choice: A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

机译：编辑选择：MEK1 / MEK2抑制剂曲美替尼（GSK1120212）与多西他赛相比在KRAS突变晚期非小细胞肺癌（NSCLC）中的II期随机研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundKRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC.

机译：背景技术在25％的非小细胞肺癌（NSCLC）中检测到KRAS突变，并且没有针对该亚群的靶向疗法被批准。曲美替尼是MEK1 / MEK2的选择性变构抑制剂，在KRAS突变型NSCLC中表现出临床前和临床活性。我们报告了一项II期试验，将曲美替尼与多西他赛治疗晚期KRAS突变型NSCLC患者进行了比较。

著录项

期刊名称 Annals of Oncology
作者
G. R. Blumenschein Jr; E. F. Smit; D. Planchard; D.-W. Kim; J. Cadranel; T. De Pas; F. Dunphy; K. Udud; M.-J. Ahn; N. H. Hanna; J.-H. Kim; J. Mazieres; S.-W. Kim; P. Baas; E. Rappold; S. Redhu; A. Puski; F. S. Wu; P. A. Jänne;
展开▼
作者单位

展开▼
年(卷),期 -1(26),5
年度 -1
页码 894–901
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
trametinib MEK inhibitor docetaxel NSCLC KRAS progression-free survival;

机译：卡培替尼;MEK抑制剂;多西他赛;NSCLC;KRAS;无进展生存期;

相似文献

外文文献
中文文献
专利

1. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) [J] . Blumenschein G. R. Jr., Smit E. F., Planchard D., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第5期

机译：MEK1 / MEK2抑制剂曲美替尼（GSK1120212）与多西他赛相比在KRAS突变晚期非小细胞肺癌（NSCLC）中的随机II期研究
2. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial [J] . W.E.E.Eberhardt, B.E.Johnson, Y.Sun, European Journal of Cancer Supplements . 2009,第2期

机译：9001 Vandetanib联合多西他赛与多西他赛作为晚期非小细胞肺癌（NSCLC）患者的二线治疗：一项随机，双盲III期临床试验
3. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial [J] . W.E.E.Eberhardt, B.E.Johnson, Y.Sun, European Journal of Cancer Supplements . 2009,第2期

机译：9001 Vandetanib联合多西他赛与多西他赛作为晚期非小细胞肺癌（NSCLC）患者的二线治疗：一项随机，双盲III期临床试验
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Editors choice: A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer [O] . A. A. Chiappori, T. Kolevska, D. R. Spigel, -1

机译：编辑选择：端粒酶抑制剂imetelstat作为晚期非小细胞肺癌维持治疗的随机II期研究
7. B3-01: A randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with previously treated advanced non-small-cell lung cancer [O] . Sekine Ikuo, Ichinose Yukito, Nishiwaki Yutaka, 2007

机译：B3-01：一项随机III期研究，比较吉非替尼（IRESSA）与多西他赛在日本先前接受过治疗的晚期非小细胞肺癌患者中的总体生存率

Editors choice: A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

摘要

著录项

相似文献

相关主题

期刊订阅